Mahdi Taha, DO, FACOI, FACP is Lead Author of Case Study Demonstrating Importance of Genomic Testing in Early identification and Treatment of Cancer
FORT MYERS, Fla., May 7, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist and hematologist Mahdi Taha, DO, FACOI, FACP is lead author and Kayla Haines, APRN is co-author of a case study published in JCO® Precision Oncology detailing the importance of genomic testing in identifying cancer and guiding targeted treatment decisions that enhance overall survival, with a focus on metastatic prostate cancer.
- Inherited genetic mutations are known to increase risk for many forms of cancer in women and men.
- Specifically, mutations in the breast cancer genes (known as BRCA1 and BRCA2) are the cause of aggressive forms of prostate cancer, the second most common cancer diagnosed in American men.
- The article details the case of an 85-year-old male patient who presented to FCS for evaluation and treatment for metastatic prostate cancer with a rising PSA.
- "Had genomic testing never been done on our patient, the BRCA2 mutation would have been unknown to the daughter," added Dr. Taha.